Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harmony Biosciences Holdings, Inc. filings document a commercial-stage pharmaceutical issuer focused on rare neurological diseases and its WAKIX-centered operating results. Form 8-K reports furnish quarterly and annual financial results, preliminary net product revenue, revenue guidance, investor presentations, and clinical-program updates.
Governance filings include definitive proxy materials for annual meeting matters, board elections, executive compensation, and shareholder voting procedures. Material-event reports also record executive appointments, separations, compensatory arrangements, board changes, Regulation FD disclosures, and exhibit-based updates related to the company’s business and pipeline.
Harmony Biosciences Holdings, Inc. reported continued profitability for the quarter ended March 31, 2026. Net product revenue rose to $215.4 million from $184.7 million a year earlier, driven by growth of WAKIX in narcolepsy.
Higher research and development spending, including $32.0 million of acquired in-process R&D and new license upfronts, reduced net income to $32.5 million from $45.6 million. Diluted earnings per share were $0.55 versus $0.78 in the prior-year period.
Harmony ended the quarter with strong liquidity, holding $589.4 million in cash and cash equivalents and $281.1 million in short- and long-term investments, and a $160.0 million term loan outstanding. Management believes current cash, investments and cash flows will fund operations and planned investing activities for at least the next twelve months.
Harmony Biosciences Holdings, Inc. announced a chief financial officer transition, with Sandip Kapadia stepping down and Glenn Reicin appointed CFO effective April 14, 2026. Kapadia will receive severance under a Separation Agreement consistent with his employment and award agreements, in exchange for a release of claims and ongoing covenants.
Reicin’s Employment Agreement provides a $500,000 annual base salary, a target annual bonus equal to 50% of salary, and a stock option grant with a grant date fair value of $3,000,000, vesting over four years. In a concurrent press release, Harmony reiterated its 2026 net product revenue guidance for WAKIX of $1.0 to $1.04 billion.
Harmony Biosciences Holdings, Inc. reported that Chief Commercial Officer Adam H. Zaeske exercised restricted stock units into common stock and had shares withheld for taxes. On April 7, 2026, 7,500 restricted stock units converted into 7,500 shares of common stock at a stated price of $0.00 per share, reflecting a stock-based compensation event rather than a market purchase.
To cover required income tax withholdings tied to the RSU vesting, 3,173 shares of common stock were disposed of at $27.62 per share through issuer withholding, leaving Zaeske with 4,327 shares of common stock held directly after these transactions. The RSU award is scheduled to vest in four equal annual installments beginning on April 7, 2026, contingent on continued service.
Harmony Biosciences Holdings, Inc. reported that Chief Operating Officer Peter Anastasiou received a grant of stock options covering 212,241 shares of common stock. The options have an exercise price of $27.74 per share and expire on April 2, 2036.
According to the grant terms, 25% of the underlying shares vest on April 2, 2027, with the remaining options vesting on a quarterly basis until the fourth anniversary of the grant date, contingent on his continued service with the company.
Harmony Biosciences Holdings, Inc. director Troy A. Ignelzi reported receiving a stock option grant for 17,710 shares of common stock. The option has an exercise price of $27.74 per share and expires on April 2, 2036. This is a compensation-related award, not an open-market trade.
The option will vest in 36 equal monthly installments beginning on May 2, 2026, meaning the right to exercise the option will phase in gradually over three years.
Harmony Biosciences Holdings, Inc. director Troy A. Ignelzi filed an initial Form 3, which is a required statement of beneficial ownership for insiders. This filing lists him as a director of the company but shows no reported transactions or specific share holdings at this time.
Harmony Biosciences Holdings, Inc. is calling a virtual 2026 annual meeting on May 14, 2026 at 1:00 p.m. Eastern Time to consider key governance and compensation matters. Holders of common stock at the March 17, 2026 record date, when 57,867,389 shares were outstanding, may vote online.
Stockholders will vote on electing four Class III directors (Andreas Wicki, Geno Germano, Troy Ignelzi and Ron Philip) to terms ending at the 2029 meeting, ratifying Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approving on a non-binding basis the compensation of named executive officers.
The board, which is largely independent and organized into audit, compensation, and nominating and corporate governance committees, emphasizes pay-for-performance through base salary, annual cash incentives and equity awards. 2025 bonuses for named executives were generally paid at or near target based on revenue, clinical, transaction, financial and talent goals, and the company maintains an anti-hedging policy and a clawback policy on incentive pay.
Harmony Biosciences Holdings, Inc. appointed Peter Anastasiou as Senior Executive Vice President and Chief Operating Officer, effective April 2, 2026, and he resigned from the board to assume the executive role. The company also appointed Troy Ignelzi as a Class III director and announced that Antonio Gracias will not stand for re-election at the 2026 annual meeting.
Under his employment agreement, Anastasiou will receive a $600,000 annual base salary, a target annual bonus equal to 55% of salary, and a stock option award with a grant date fair value of $3,700,000, together with severance protections and customary restrictive covenants. Ignelzi will serve on the Audit and Compensation Committees and is deemed an independent director, while the board has nominated Geno J. Germano for election at the 2026 annual meeting.
Harmony Biosciences Holdings Inc: an amendment to a Schedule 13G/A reports that The Vanguard Group holds 0 shares of common stock, representing 0 % of the class. The filing explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report beneficial ownership separately.